Hollencrest Capital Management’s Edwards Lifesciences EW Stock Holding History

Hollencrest Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.9K	Sell	121 -36,000	-100%	-$3.02M	﹤0.01%	809
2026 Q1	$2.89M	Hold	36,121	–	–	0.11%	90
2025 Q4	$3.08M	Hold	36,121	–	–	0.11%	84
2025 Q3	$2.81M	Hold	36,121	–	–	0.1%	86
2025 Q2	$2.83M	Hold	36,121	–	–	0.12%	80
2025 Q1	$2.62M	Sell	36,121 -2	-0%	-$143	0.11%	79
2024 Q4	$2.67M	Hold	36,123	–	–	0.11%	80
2024 Q3	$2.38M	Buy	36,123 +2	+0%	+$145	0.1%	85
2024 Q2	$3.34M	Hold	36,121	–	–	0.15%	67
2024 Q1	$3.45M	Buy	36,121 +34,691	+2,426%	+$2.91M	0.16%	63
2023 Q4	$109K	Hold	1,430	–	–	0.01%	363
2023 Q3	$99.1K	Hold	1,430	–	–	0.01%	362
2023 Q2	$135K	Hold	1,430	–	–	0.01%	341
2023 Q1	$118K	Buy	1,430 +1,261	+746%	+$99.1K	0.01%	350
2022 Q4	$12.6K	Buy	+169	New	+$13K	﹤0.01%	690

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Hollencrest Capital Management's EW Position: Q2 2026 in Review

Hollencrest Capital Management reduced its Edwards Lifesciences (EW) stake by 100% in Q2 2026, selling an estimated $3.02M and leaving 121 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #809.

Hollencrest Capital Management first reported a position in EW in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.45M in Q1 2024. 1,330 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Hollencrest Capital Management held 121 shares of Edwards Lifesciences worth $10.9K as of Q2 2026.
Hollencrest Capital Management sold 36,000 Edwards Lifesciences shares in Q2 2026, an estimated $3.02M.
Edwards Lifesciences made up ﹤0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #809 holding.
Hollencrest Capital Management first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 15 quarters since.
Hollencrest Capital Management's Edwards Lifesciences position peaked at $3.45M in Q1 2024.
1,330 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.